Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases

Abstract

BackgroundQVA149 is a combination of indacaterol and glycopyrronium (Dahl, R. et al. Respir Med 2013;107:1558-67).AimTo investigate the interaction of indacaterol and glycopyrroniumin in inducing acute bronchodilation.MethodsBronchial rings from 6 patients were incubated in Krebs-Henseleit solution (37°C) aerated with O2/CO2 (95/5%) under 0.5–1.0 g tension. The effect of drugs (% maximal response to papaverine) administered alone or in combination at isoeffective concentrations was assessed at sub-maximal contraction (70% maximum, EC₇₀) induced by acetylcholine. Lung function of 16 COPD patients was assessed after inhalation of indacaterol 150µg and glycopyrronium 50µg, alone or in combination. Spirometric data were normalized for the maximal effect induced by salbutamol. Drug mixture effects were analyzed by Bliss Independence (BI) theory. Values (ex vivo n=3, in vivo n=16) are mean±SEM.ResultsBoth glycopyrronium and indacaterol completely relaxed bronchial rings in a concentration-dependent manner, glycopyrronium was more potent than indacaterol (pD₂: 8.75±0.04 and 7.68±0.22, respectively; P<0.01). The combination produced synergistic interaction at low concentrations inducing EC₃₀ (BI delta effect: 0.26±0.03, P<0.05). In COPD patients, glycopyrronium and indacaterol in combination significantly anticipated at 15 min post-administration the mean peak of bronchodilatory effect, compared with drugs administered alone. Synergistic interaction was detected for FEV₁ at 15 min post-administration and additive effect persisted between 5 min and 180 min post-inhalation.ConclusionsQVA149 ensures a broncholytic effect that is much broader than what can be observed with the single monocomponents.

Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola, L. Calzetta, A. Segreti, F. Facciolo, P. Rogliani, M. G. Matera (Rome, Naples, Italy). Translational study searching for synergy between glycopyrronium and indacaterol. Eur Respir J 2014; 44: Suppl. 58, 1516

Member's Comments

No comment yet.

Related content which might interest you: Mixed treatment analysis comparing tiotropium HandiHaler® and Respimat® Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Interaction between RPL554 and glycopyrronium bromide in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Overall and cardiovascular safety of aclidinium bromide in patients with COPD: Results of a pooled analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Interaction between aclidinium bromide and formoterol fumarate in small human airways Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Inhaler technique – A time to re-educate patients? Source: International Congress 2014 – Clinical management of lung diseases: from bronchi to pleura Year: 2014 Inflammation in COPD patients before and after roflumilast treatment Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Lung deposition analysis of two formulations of fluticasone/salmeterol HFA pMDI in stable asthma patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Safety of tiotropium in renally impaired patients Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status Source: International Congress 2014 – Asthma and COPD management Year: 2014 Abediterol has higher bronchodilatory potency and reduced cardiac effects versus other long-acting beta2-agonists in dogs Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Efficacy and safety of abediterol, a long-acting beta2-adrenergic agonist (LABA); three phase II trials in asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014